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BACKGROUND & AIMS:Abbreviations used in this pa
hepatic venous pressure grad
odds ratio; RCT, randomized co
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92In unselected patients with cirrhosis, those with reductions in hepatic venous pressure gradient
(HVPG) to below a defined threshold (responders) have a reduced risk of variceal hemorrhage (VH)




97We collected data from 15 studies of primary or secondary prophylaxis of VH that reported data
on VH and death in responders vs nonresponders. We included studies in which data on ascites
at baseline and on other relevant outcomes during follow-up evaluation were available. We









108Of the 1113 patients included in the studies, 968 patients (87%) had been treated with
nonselective b-blockers. In 993 patients (89%), HVPG response was defined as a decrease of
more than 20% from baseline (>10% in 11% of patients) or to less than 12 mm Hg. In the 661
patients without ascites, responders (n [ 329; 50%) had significantly lower odds of events
(ascites, VH, or encephalopathy) than nonresponders (odds ratio [OR], 0.35; 95% CI, 0.22–0.56).
Odds of death or liver transplantation were also significantly lower among responders than
nonresponders (OR, 0.50, 95% CI, 0.32–0.78). In the 452 patients with ascites, responders (n [
188; 42%) had significantly lower odds of events (VH, refractory ascites, spontaneous bacterial
peritonitis, or hepatorenal syndrome) than nonresponders (OR, 0.27; 95% CI, 0.16–0.43).
Overall, odds of death or liver transplantation were lower among responders (OR, 0.47; 95% CI,
0.29–0.75). No heterogeneity was observed among studies.per: HRS, hepatorenal syndrome; HVPG,
ient; NSBB, nonselective b-blocker; OR,
ntrolled trial; VH, variceal hemorrhage.
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177In a meta-analysis of clinical trials, we found that patients with cirrhosis with and without
ascites who respond to treatment with nonselective b-blockers (based on reductions in HVPG)













































224Cirrhosis is the end stage of any chronic liver dis-ease and, based on a large body of evidence, it
now is classified into 2 distinct stages: compensated and
decompensated. Each stage differs significantly in the
prognosis, predominant pathophysiological mechanisms,
and predictors of death.1–4
Nonselective b-blockers (NSBBs) have been the main-
stay of therapy of portal hypertension since 1981 when
Lebrec et al5 showed the efficacy of propranolol in reducing
portal pressure. Since then, many randomized controlled
trials have shown that NSBBs are effective in preventing
variceal hemorrhage, both first and recurrent, and there-
fore NSBBs are considered first-line therapy in the primary
and secondary prophylaxis of variceal hemorrhage.6
Because NSBBs, by reducing portal pressure, may pre-
vent not only variceal hemorrhage but other complications
of portal hypertension, many studies have correlated the
decrease in portal pressure (as determined by the hepatic
venous pressure gradient [HVPG]) with the prevention of all
complications of cirrhosis, including death. In a meta-
analysis by D’Amico et al7 that included 12 studies
(including 943 patients with cirrhosis), HVPG responders,
definedas thosewith anHVPGreduction to12mmHgor less
or 20% or more from baseline had a significantly lower risk
of bleeding and death. However, all studies included in the
D’Amico et al7 meta-analysis combined results from patients
with both compensated and decompensated cirrhosis.
Because the effect of NSBBs on portal pressure and
outcomes may differ in these 2 different stages of
cirrhosis8 and because it has been suggested that NSBBs
may be deleterious in patients with refractory ascites,9,10
we considered it important to update the D’Amico et al7
meta-analysis by not only adding data from additional
recent studies reporting HVPG response and outcomes
but, more importantly, to stratify patients by the pres-
ence or absence of ascites and to report on clinically
relevant outcomes. For this study, we considered ascites
as the hallmark of decompensation because it is the most
common decompensating event, it is the only one that is
continuous (as opposed to variceal hemorrhage and he-
patic encephalopathy, which are episodic), and because it
is the most likely to be recorded accurately in study









We performed a meta-analysis to pool data from pa-
tients with cirrhosis included in studies (randomizedFLA 5.6.0 DTD  YJCGH56552_proof controlled trials or other) that assessed the difference in
clinically relevant outcomes between HVPG responders
and nonresponders relating to the 2 main prognostic
stages of cirrhosis, compensated or decompensated,
which in this study is defined as the absence or presence
of ascites, respectively. This meta-analysis was conduct-
ed and reported according to the Quality Assessment of
Systematic Reviews and Meta-Analyses of the National
Institutes of Health, last updated in March 2014.11
Eligibility Criteria
Studies that included patients with cirrhosis and
varices undergoing treatment with NSBBs to prevent
first or recurrent esophageal variceal hemorrhage
were included in this analysis if the following criteria
were met: (1) patients included in the study had at
least 2 measurements of HVPG performed, at baseline
(before therapy) and during therapy; (2) the published
report included the number of patients who were
HVPG responders vs nonresponders; and (3) informa-
tion regarding the presence or absence of ascites at
baseline and relevant clinical outcomes during follow-
up evaluation were available for each of the responder
groups.
Exclusion Criteria
Case reports, editorials, letters, review articles, and
guidelines were excluded from the analysis. We also
excluded studies in which cirrhosis developed after liver
transplantation. The D’Amico et al7 meta-analysis found
the long interval (5.3 mo) between HVPG measurements
observed in 1 study12 to be the main predictor of het-
erogeneity, therefore this study12 and any other study
with a mean/median interval between HVPG measure-
ments of 5 months or longer were excluded.
Information Sources and Search
The studies conducted until December 2005 were
identified from the D’Amico et al7 meta-analysis. Studies
conducted from January 1, 2006, to November 30, 2015,
were identified by searching electronic databases using
the terms “hepatic venous pressure gradient” or “HVPG,”
limiting the search to human studies. This search was
performed in MEDLINE via PubMed, Embase using the
ScienceDirect interface, and The Cochrane Central Reg-
ister of Controlled Trials. Publications in personal
reference lists and citation sections of the recovered26 June 2019  11:22 pm  ce DVC
What You Need to Know
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294articles also were reviewed and abstracts presented at
meetings of the American Association for the Study of
Liver Diseases and the European Association for the
Study of the Liver were searched manually.In patients with cirrhosis, lowering portal pressure
mostly by treatment with a nonselective b-blocker
(NSBB) is associated with lower rates of variceal
hemorrhage and death. However, it is not clear if the
benefits of this treatment apply to patients with or
without ascites.
Findings
In a meta-analysis of 15 studies, we found outcomes
(not only variceal hemorrhage) and death to be
significantly lower in patients with cirrhosis with a
mostly NSBB-induced reduction in portal pressure.
This beneficial effect applies to patients with and
without ascites
Implications for patient care
Patients with cirrhosis, with or without ascites, who
have reductions in portal pressure mostly after
treatment with NSBBs are at reduced risk for adverse










































335Study Selection and Data Collection Process
Two authors (L.T. and G.G.-T.) independently
assessed titles and abstracts of studies identified in the
primary search. If the title and/or abstract showed that
the article did not meet inclusion criteria, the study was
excluded. If the inclusion criteria could not be assessed
from the title/abstract with certitude, the full-text article
was evaluated to determine eligibility. Disagreements
were resolved by discussion between L.T. and G.G.-T.
Once studies that met inclusion criteria had been
selected and because data regarding the presence or
absence of ascites and clinical outcomes specific for each
of these subgroups and for each of the responder groups
(responder vs nonresponder) could not be extracted
from published studies, principal investigators of eligible
studies were contacted to obtain data for all subgroups
in their trials. Specifically, we provided a data collection
form divided into HVPG responder vs nonresponder
groups (providing the numbers for each group that had
been reported in the published article), and the principal
investigators then provided data on the presence or
absence of ascites and on relevant clinical outcomes (see
later) for each responder group separately. Therefore,
this was not an individual meta-analysis and the objec-
tive was to analyze the development of clinical outcomes
separately in HVPG responders vs nonresponders (as
defined in each of the studies) stratified by the presence
or absence of ascites. To include only unique patients,
when the same patient population was used in multiple
publications, the authors were asked to provide data
from the most recent publication that included all pa-
tients (in which case the previous publication would not
be considered) or to report only on the additional pa-
tients in the newer publication (in which case both
publications would be cited). Authors were asked to
exclude data from patients with only 1 HVPG measure-
ment. The original data sets were checked for
completeness and internal consistency and amended












348Data Collected on Outcomes
Relevant outcomes were defined separately for pa-
tients without ascites (compensated) and those with
ascites (decompensated), as follows.
For patients without ascites, primary outcomes were
the development of ascites, variceal hemorrhage (first in
primary prophylaxis studies, recurrent in secondary
prophylaxis studies), or encephalopathy. For patients
with ascites, primary outcomes were the development of
variceal bleeding (first in primary prophylaxis studies,FLA 5.6.0 DTD  YJCGH56552_proof recurrent in secondary prophylaxis studies) or refractory
ascites, spontaneous bacterial peritonitis, hepatorenal
syndrome, or encephalopathy. For patients in both
groups, data were collected for both transplant and
death. However, because the number of transplanted
patients was small (n ¼ 76), death or transplant (death/
transplant) was used as a secondary end point.
Authors of each of the publications were asked to
report on clinical outcome as follows: (1) bleeding or re-
bleeding alone (according to whether the patient was in
a primary prophylaxis study/group or a secondary pro-
phylaxis study/group; (2) bleeding or re-bleeding plus
another outcome; and (3) any other clinical outcome
without bleeding or re-bleeding. For the final analysis, all
of these outcomes were combined. Careful initial evalu-
ation was performed to ensure completeness of data, and
to check the consistency of the results of the primary
analyses for each trial with published reports.Statistical Analysis
Meta-analyses were performed separately for pa-
tients without ascites and for those with ascites, and also
was performed separately for patients enrolled in pri-
mary prophylaxis studies and those enrolled in second-
ary prophylaxis studies. Because the results of each
study had dichotomous frequency data, a meta-analysis
was performed by calculating odds ratios (ORs) and
95% CIs. Because the differences in the patients enrolled,
the way the intervention was administered, and the way
the outcome was measured may have had an impact on26 June 2019  11:22 pm  ce DVC
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416the magnitude of the effect, we chose to pool data and
compare it using a random-effects model.13 A P value
less than .05 was considered significant. Statistical het-
erogeneity was calculated by the I2. Values less than
30%, 30% to 59%, 60% to 75%, and greater than 75%
were classified as low, moderate, substantial, and
considerable heterogeneity, respectively.14 All analyses
were performed using the software Review Manager


















































A total of 459 unique citations were identified using
our search criteria (Supplementary Figure 1). After
excluding 420 studies because they did not report data on
follow-upHVPG, 30 studies because they did not report on
outcomes, and 1 study15 because the median time be-
tween the baseline and follow-up HVPGwas longer than 5
months (13 months in compensated patients and 8
months in decompensated patients), 8 studies published
between January 2006 and November 2015 met our in-
clusion criteria. These 8 studies were added to 12 studies
published before December 2005 as identified by D’Amico
et al7 (Supplementary Figure 1).We could not identify any
eligible study published in abstract form that was not
subsequently published in full.
Additional data on the outcomes of patients with and
without ascites (separately) were requested from the
authors of the 20 eligible studies. Original data were no
longer available for 4 of them (including the study from
McCormick et al12), and data from 1 publication16 was
duplicated in a second publication17 and therefore was
excluded. Therefore, the meta-analysis includes data
from 15 studies17–31 (Supplementary Figure 1).
Characteristics of studies and patients. The charac-
teristics of the 15 studies are shown in Table 1. Ten
studies were case-series and 5 were randomized
controlled trials (RCT), and alcohol was the main etiology
of cirrhosis in most studies.
Overall, the 15 selected studies included 1341 pa-
tients, of whom 228 were excluded (124 patients did not
have a second HVPG performed, 72 patients had been
reported in other studies, and 32 patients were tested
after a single intravenous dose of propranolol). There-
fore, data from 1113 unique patients were analyzed. Of
these, 452 (40.6%) had ascites. Notably, and as expected,
the mean HVPG levels were higher in patients with as-
cites than in those without ascites (Table 2).
Table 3 shows the different outcomes including
death/liver transplant rates by the presence or absence
of ascites, according to the HVPG response category
(responders vs nonresponders), as defined in each of the
studies. Except for 2 studies19,25 (all patients taking
NSBBs for primary prophylaxis) defining HVPGFLA 5.6.0 DTD  YJCGH56552_proof responders as those patients achieving a reduction of
more than 10% or a decrease to less than 12 mm Hg, the
remaining 13 studies defined HVPG response as a
decrease to less than 12 mm Hg or a reduction of more
than 20% from baseline. Notably, raw data were avail-
able for a study in which the original publication had
defined only HVPG response as a decrease in HVPG to
less than 12 mm Hg20 so that response could be rede-
fined as a decrease greater than 20% or a decrease less
than 12 mm Hg to be consistent with the majority of
studies. Table 3 also shows the specific pharmacologic
therapy. Notably, of 1113 unique patients, only 145
(13%) were not on active pharmacologic treatment (39
were on placebo and 106 received endoscopic treatment
only) (Table 3). Supplementary Table 1 shows the HVPG
methodology used in each study.Patients Without Ascites (n¼ 661)
Of 661 patients without ascites, 332 did not have a
history of variceal hemorrhage (included in primary
prophylaxis studies) and 329 had a history of variceal
hemorrhage (included in secondary prophylaxis studies).
Except for 85 patients (12.9%) analyzed in 2
studies19,25 in whom response was defined as an HVPG
decrease of more than 10% or a decrease to less than 12
mm Hg (all patients taking NSBBs for primary prophy-
laxis), in the remaining 576 (87.1%) patients, HVPG
response was defined as a decrease to less than 12 mm
Hg or more than a 20% reduction from baseline.
Overall, responders (49.8%) had a significantly lower
rate of clinical events (variceal hemorrhage, ascites, or
encephalopathy) than nonresponders (OR, 0.35; 95% CI,
0.22–0.56) (Figure 1A), both in patients included in
primary prophylaxis studies (OR, 0.28; 95% CI,
0.13–0.58) and in secondary prophylaxis studies (OR,
0.41; 95% CI, 0.22–0.78) without significant heteroge-
neity (P ¼ .10) (Figure 1A)
Death/transplant rates also were significantly lower
among responders (OR, 0.50; 95% CI, 0.32–0.78)
(Figure 1B) in both patients in primary (OR, 0.44; 95%
CI, 0.20–0.98) or secondary prophylaxis (OR, 0.55; 95%
CI, 0.32–0.95) studies without significant heterogeneity
(P ¼ .28) (Figure 1B).Patients With Ascites (n ¼452)
Of the 452 patients with ascites, 172 did not have a
history of variceal hemorrhage (included in primary
prophylaxis studies) and 280 had a history of variceal
hemorrhage (included in secondary prophylaxis studies).
Except for 35 patients (7.7%) analyzed in 1 study25 in
whom response was defined as an HVPG decrease of
more than 10% or a reduction to less than 12 mm Hg (all
patients were on NSBBs for primary prophylaxis), in the
remaining 417 (92.3%) patients, HVPG response was26 June 2019  11:22 pm  ce DVC
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Cirrhosis, esophageal varices, no
previous variceal bleeding
Severe hepatic disease, known neoplasms
Severe nonhepatic disorders




Case series Cirrhosis, large esophageal varices,
no previous variceal bleeding,
ascites, jaundice, or
encephalopathy
Age <18 or >80 y, Child score >10, HCC,
splanchnic venous thrombosis, treatment with
diuretics or vasoactive drugs, contraindications
to NSBB, comorbidity with life expectancy <1 y
2001–2008 62 49 HCV, 62
Merkel et al,21 2000
Hepatology
Case series Cirrhosis, medium–large esophageal
varices or small varices with RWM,
no previous variceal bleeding, no
previous treatment for PH




Reiberger et al,22 2013
Gut
Case series Cirrhosis, esophageal varices, no
previous bleeding, HVPG >12
mm Hg
Age<18 y, HCC or other malignancy, prehepatic or
posthepatic causes of portal hypertension,
severe liver failure, uncontrolled HE, alcohol or
intravenous drug abuse, renal failure,
contraindications to NSBB
2008–2012 53 77 Alcohol, 55
Sharma et al,23 2009
Aliment Pharmacol Ther
Case series Cirrhosis, medium–large esophageal
varices  RWM, no previous
variceal bleeding
Age <18 or >70 y, previous varices endoscopic
treatment, use of NSBB in previous 3 mo,
history of surgery for portal hypertension, PVT,
Child score >13, cardiopulmonary or renal
failure, any neoplasm, contraindications to
NSBB, concomitant treatment for HBV or HCV
2004–2005 47 79 Virus-related,
61
Turnes et al,24 2006
Am J Gastroenterol
Case series Cirrhosis, esophageal varices, no
previous variceal bleeding, HVPG
>12 mm Hg
HCC, PVT, contraindications to NSBB, cholestatic
liver disease
1994–2000 58 67 NA
Villanueva et al,25 2009
Gastroenterology
Case series Cirrhosis, large esophageal varices,
no previous variceal bleeding
Age <18 or >80 y, HCC, Child score >13, PVT,
contraindications to NSBB, previous treatment
for portal hypertension, comorbidity with life
expectancy <1 y
1999–2005 62 57 HCV, 42;
alcohol,
34
Abraldes et al,18 2003
Hepatology
Case series Cirrhosis, variceal bleeding, HVPG
>12 mm Hg
HCC, PVT, contraindications to NSBB, cholestatic
liver disease
NA 54 66 Alcohol, 51
Augustin et al,17 2012
Hepatology
Case series Cirrhosis, variceal bleeding Age >80 y, Child score >13, failure to control the
index bleeding, current active therapy with
NSBB and ISMN o Q25endoscopic variceal
obliteration, contraindications to NSBB
or ISMN, advanced HCC, severe
comorbidity, PVT, HVPG <10 mm Hg







































































































































































































































































































































































































































vasoactive drugs, antibiotics, and
endoscopy
Age <18 or >75 y, pregnancy; Child score >13,
HCC, renal failure, comorbidity with reduced life
expectancy, contraindications to NSBB or
ISMN, PVT, previous treatment to prevent
rebleeding, treatment with EVL in the 3 months
before, bleeding from isolated gastric or ectopic
varices
2003–2005 56 75 Alcohol, 51
Villanueva et al, 199627
N Engl J Med
Randomized
controlled trial
Cirrhosis, variceal bleeding Age <18 y, Child score >12, advanced HCC, other
cancer, previous sclerotherapy, failure of
medical therapy to control the bleeding
1991–1994 59 67 Alcohol, 57
Villanueva et al,28 2001
N Engl J Med
Randomized
controlled trial
Cirrhosis, variceal bleeding Age <18 y, Child score >12, advanced HCC,
previous variceal endoscopic treatment, history
of surgery for portal hypertension, previous
treatment with NSBB and ISMN, failure of
medical therapy to control the bleeding,
comorbidity with life expectancy <6 mo




Villanueva et al,29 2004
J Hepatol
Case series Cirrhosis, variceal bleeding Age <18 y, Child score >12, advanced HCC,
previous variceal endoscopic treatment, history
of surgery for portal hypertension, previous
treatment with NSBB and ISMN, failure of
medical therapy to control the bleeding,
comorbidity with life expectancy <6 mo








Cirrhosis, variceal bleeding Child score >12, advanced HCC, previous variceal
endoscopic treatment, previous treatment with
NSBB and ISMN




Bureau et al,31 2002
Hepatology
Case series Cirrhosis, medium–large esophageal
varices
Age <18 or >75 y, HCC, PVT, previous treatment
or contraindication to NSBB and ISMN, history
of surgery for portal hypertension
1997–2000 53 62 Alcohol, 76
EVL, endoscopic varices legation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient; ISMN, isosorbide mononitrate; NA, not
















































































































































































































































































































































































































































Mean HVPG  SD in
unique patients without
ascites, mm Hga









Groszmann et al,20 1990
Gastroenterology
102 84 84 43/41 3 17.4  3.6 15.4  3.8 19.9  5.2 17.6  4.9
Hernandez-Gea et al,19 2012
Am J Gastroenterol
78 78 47 47/0 2.4  1.1 16.9  3 15.7  3 NA
Merkel et al,21 2000
Hepatology
49 49 49 27/22 1.5 17.4 14.3 20.2 16.2
Reiberger et al,22 2013
Gut
104 104 104 93/11 1.7  0.6 20.3  4.1 16.0  3.7 22.3  4.3 17.9  2.6
Sharma et al,23 2009
Aliment Pharmacol Ther
56 56 56 29/27 1 or 2b 17.8 16.3 18.2 16.1
Turnes et al,24 2006
Am J Gastroenterol
71 71 71 46/25 5 17.8 15.6 19.6 17.0
Villanueva et al,25 2009
Gastroenterology
73c 73 73 38/35 3.1  1.1 17.5  3 15.6  4 19.1  3 16.9  4
Secondary prophylaxis
Abraldes et al,18 2003
Hepatology
73 73 73 50/23 4.1 18.7 16.1 18.1 15.4
Augustin et al,17 2012
Hepatology
90 90 90 57/33 0.25 17.3 14.1 19.6 16.2
García-Pagán et al,26 2009
Gut
158 135 135 94/41 1 20 17 21 18
Villanueva et al,27 1996
N Engl J Med
86 62 62 35/27 3.5 16.8  3 14.9  4 17.4  4 16.6  4
Villanueva et al,28 2001
N Engl J Med
144 95 95 32/63 2.3  1 18.9  4 16.4  4 20.6  4 18.2  3
Villanueva et al,29 2004
J Hepatol
132 132 91 34/57 2.5 18.3  3 14.5  3 20.7  4 17.5  4
Villanueva et al,30 2009
Aliment Pharmacol Ther
59 49 49 15/34 2.2  1.2 16.9  4 14.3  3 21.7  5 18.4  5
Primary and secondary prophylaxis
Bureau et al,31 2002 Hepatology 20 (primary
prophylaxis)
20 20 9/11 0.6 16.8 11.4 17.8 14.8
14 (secondary
prophylaxis)
14 14 12/2 1 22.2 18.6 22.5 16.5
HVPG, hepatic venous pressure gradient; NA, not applicable.
aData not in original publication, provided by authors.
bOne month in responders to propranolol; 2 months for nonresponders to propranolol in whom isosorbide mononitrate was added.









































































































































































































































































































































































































































































16 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 43 R 15 0 NA NA NA 1
NR 28 3 NA NA NA 4
Ascites 41 R 15 2 NA NA NA 2
NR 26 3 NA NA NA 5
Hernandez-Gea
et al,19 2012 Am J
Gastroenterol
47 Nadolol 0 53 HVPG decrease10% No ascites 47 R 20 0 1 7 0 4
NR 27 0 8 16 1 12
Ascites NA R NA NA NA NA NA NA
NR NA NA NA NA NA NA





0 36 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 27 R 17 0 1 1 1 2
NR 10 2 0 3 0 2
Ascites 22 R 13 1 0 4 0 4








19 HVPG <12 mm Hg or
HVPG decrease
20%
No ascites 93 R 68 3 2 13 5 4
NR 25 2 3 7 2 6
Ascites 11 R 7 1 1 4 1 5
NR 4 2 0 2 1 3





0 24 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 29 R 12 0 0 1 0 1
NR 17 1 1 0 0 0
Ascites 27 R 15 1 0 0 0 0
NR 12 2 0 0 0 1





0 68 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 46 R 16 1 1 8 3 6
NR 30 4 6 8 1 13
Ascites 25 R 9 0 0 4 0 3




73 Nadolol 0 25 HVPG <12 mm Hg or
HVPG decrease
10%
No ascites 38 R 26 1 0 6 0 2
NR 12 0 4 4 0 5
Ascites 35 R 21 0 0 12 4 4






0 70 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 50 R 19 3 2 3 4 1
NR 31 6 9 4 3 8
Ascites 23 R 9 0 1 4 0 0





0 48 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 57 R 32 8 5 3 3 7
NR 25 0 3 11 4 9
Ascites 33 R 16 3 0 4 2 4



































































































































































































































































































































































































































00 15 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 94 R 36 3 2 5 2 4
NR 58 11 6 6 2 7
Ascites 41 R 12 0 1 3 0 2
NR 29 2 5 10 1 6
Villanueva et al,27







18 HVPG <12 mm Hg or
HVPG decrease
20%
No ascites 35 R 14 1 0 3 1 2
NR 21 6 4 2 2 1
Ascites 27 R 5 0 0 4 0 1
NR 22 4 8 4 2 3
Villanueva et al,28







24 HVPG <12 mm Hg or
HVPG decrease
>20%
No ascites 32 R 13 1 0 0 0 1
NR 19 6 5 1 0 8
Ascites 63 R 18 1 3 3 2 2





0 16 HVPG 12 mm Hg or
HVPG decrease
20%
No ascites 34 R 18 3 0 3 0 2
NR 16 1 3 1 2 4
Ascites 57 R 23 0 1 8 0 5










0 34 HVPG <12 mm Hg or
HVPG decrease
>20%
No ascites 15 R 10 1 1 1 1 2
NR 5 0 1 3 0 3
Ascites 34 R 17 1 1 7 4 6
NR 17 1 6 8 2 12
Primary and secondary prophylaxis







0 28 HVPG <12 mm Hg or
HVPG decrease
>20%
No ascites 9 R 8 0 NA NA 0 0
NR 1 1 NA NA 0 1
Ascites 11 R 6 0 NA NA 0 1
NR 5 1 NA NA 0 2
No ascites 12 R 5 1 NA NA 0 1
NR 7 6 NA NA 0 2
Ascites 2 R 1 1 NA NA 0 1
NR 1 1 NA NA 0 0



































































































































































































































































































































































































































































Figure 1. Patients without ascites. (A) Outcome: any clinical event Q22. (B) Outcome: death or transplant.
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1276defined as a decrease to less than 12 mm Hg or a more
than 20% reduction from baseline.
Overall, responders (41.6%) had a significantly lower
rate of clinical events (variceal hemorrhage, refractory as-
cites, spontaneous bacterial peritonitis, hepatorenal syn-
drome, or encephalopathy) than nonresponders (OR, 0.27;
95% CI, 0.16–0.43) (Figure 2A), both in patients included in
primary (OR, 0.38; 95% CI, 0.16–0.89) and in secondary
prophylaxis studies (OR, 0.24; 95% CI, 0.12–0.48) without
significant heterogeneity (P ¼ .40) (Figure 2A).
Death/transplant rates were lower among re-
sponders (OR, 0.47; 95% CI, 0.29–0.75) (Figure 2B) both
in patients in primary (OR, 0.74; 95% CI, 0.34–1.63) or
secondary prophylaxis (OR, 0.36; 95% CI, 0.20–0.65)
without significant heterogeneity (P ¼ .69) (Figure 2B).
However, the difference was not statistically significant
in patients receiving primary prophylaxis (P ¼ .46).
Of note, the mean reduction in HVPG observed in pa-
tients with ascites (from 19.9 mm Hg at baseline to 17.2
mm Hg at follow-up evaluation, a decrease of 14%) was
lower than that observed in patients without ascites (from
18.4 to 14.9 mm Hg, a decrease of 19%). In fact, the rate of
HVPG responders was significantly lower in patients with
ascites compared with those without ascites (42% vs 50%,
respectively; P ¼ .0085). The highest HVPG response rate
was observed in patients without ascites or variceal hem-
orrhage (VH) (50%), and the lowest HVPG response rate
was in patients with ascites and prior VH (36%).
Patients Without Ascites Vs Patients With
Ascites
Subgroup (no ascites vs ascites) difference testing in
patients enrolled in primary and secondary prophylaxis
studies was performed to assess whether the effects
within each subgroup deviated significantly from the
overall effect (Supplementary Figures 2–5).
Primary prophylaxis studies. Subgroup difference
testing showed no significant differences between pa-
tients with or without ascites when looking at HVPG
response and the development of any clinical event (c2 ¼
0.31; df ¼ 1; P ¼ .58; I2 ¼ 0%) (Supplementary Figure 2)
or the death/transplant rate (c2 ¼ 0.82; df ¼ 1; P ¼ .37;
I2 ¼ 0%) (Supplementary Figure 3).
Secondary prophylaxis studies. Subgroup difference
testing showed no significant differences between pa-
tients with or without ascites when looking at HVPG
response and the development of any clinical event (c2 ¼
1.33; df ¼ 1; P ¼ .25; I2 ¼ 25%) (Supplementary
Figure 4) or the death/transplant rate (c2 ¼1.07, df ¼
1; P ¼ .30; I2 ¼ 6.8%) (Supplementary Figure 5).
Discussion
This study shows that a reduction in portal pressure,
as determined by predefined threshold reductions in
HVPG, is associated with a lower rate of relevantFLA 5.6.0 DTD  YJCGH56552_proof outcomes both in patients with and without ascites.
Because ascites is the hallmark of cirrhosis decompen-
sation, our study shows that decreases in portal pressure
are associated with better outcomes in both patients
with compensated and decompensated cirrhosis and is
proof that portal hypertension is a major mechanism in
the development of both decompensation and further
decompensation.
D’Amico et al7 had already shown an association be-
tween a reduction in HVPG to levels less than 12 mm Hg
or more than a 20% reduction from baseline and a
reduced risk of variceal hemorrhage and death. Other
studies also have shown that achievement of these he-
modynamic targets leads to a reduced risk of developing
ascites, spontaneous bacterial peritonitis, hepatorenal
syndrome (HRS), and hepatic encephalopathy.18 In pa-
tients with compensated cirrhosis who have never bled,
it has been suggested that even a target HVPG reduction
of more than 10% is associated with a reduced risk of
developing ascites, variceal bleeding, refractory ascites,
or HRS.19
However, since the publication of these studies it has
become clear that cirrhosis cannot be described as a
single-stage disease and, with decompensation being the
main determinant of prognosis, research on outcomes
has to be analyzed separately by considering the 2 main
prognostic stages of cirrhosis: compensated vs decom-
pensated.1–3 These 2 stages differ not only in terms of
prognosis, but also in terms of the underlying patho-
physiological drivers of disease progression4,32 and in
terms of clinically relevant outcomes. The most impor-
tant outcome in compensated patients is the develop-
ment of decompensation and, in decompensated
patients, the main outcome is mortality.33 Therefore, in
this meta-analysis we not only stratified patients by the
absence or presence of ascites (as the surrogate for
decompensation), but relevant clinical events were
defined differently in each of the groups.
In the subgroup of patients without ascites (ie,
compensated) we showed that decompensation (defined
as development of ascites, VH, or encephalopathy) was
reduced significantly in HVPG responders. This is not
surprising in light of a recent double-blind RCT showing
that NSBBs, compared with placebo, are associated with
a lower rate of ascites development and are associated
with a decrease in HVPG (PREDESCI RCT).34 It is note-
worthy to mention that all patients without ascites
included in the studies analyzed in our meta-analysis had
varices needing treatment and, therefore, by definition,
had clinically significant portal hypertension similar to
patients included in the PREDESCI RCT34 but with more
advanced portal hypertension. These are patients in
whom hyperdynamic circulation already is present and
the NSBB effect on HVPG is more pronounced.4,32
Importantly, HVPG response to NSBBs in our study was
associated not only with a reduced risk of decompensa-
tion, but also with a reduced risk for death/liver trans-
plantation in patients without ascites.26 June 2019  11:22 pm  ce DVC
Figure 2. Patients with ascites. (A) Outcome: any clinical event Q23. (B) Outcome: death or transplant.
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1508Results of this study in the subgroup of patients with
ascites (ie, with decompensation) are particularly rele-
vant in light of recent concerns about potential delete-
rious effects of NSBBs on renal function and a potential
risk for increased mortality in patients with ascites.9,10
Even though, as previously shown,4,8 HVPG was higher
at baseline in these patients and the rate of HVPG re-
sponders was lower than in patients without ascites, we
could show that portal pressure reduction achieved by
pharmacologic treatment was associated not only with a
lower rate of further decompensation (defined as the
development of VH, refractory ascites, spontaneous
bacterial peritonitis, HRS), but also with a decrease in
death/transplant in the overall group of patients with
ascites. The decrease in death/transplant was significant
in patients with a history of variceal hemorrhage (sec-
ondary prophylaxis studies), who likely represent a
sicker patient population. Although we did not observe a
significant benefit on the death/transplant rate in pa-
tients included in primary prophylaxis studies, there was
no indication of a higher mortality rate in this group
because the subgroup difference testing was not signifi-
cant (Figure 2B). This lack of effect on survival already
had been noted in previous meta-analyses7,35 and, in our
study, this could have been because this was the smallest
subgroup and rates of death/transplant were lower than
expected based on other studies. In addition, although in
patients with ascites who have bled from varices the
main driver of mortality is the severity of portal hyper-
tension (and therefore is affected by hemodynamic
response), in patients without variceal hemorrhage
confounders such as hepatocellular carcinoma, not
directly related to hemodynamic changes, may
contribute to overall mortality. We chose to analyze
deaths/transplant jointly because of the multinational
nature of the publications with different availability/
criteria for transplant and the timespan of the studies
(with the earliest in 1990 when transplant rarely was
performed). The number of transplants in the whole
series was only 76, representing 23% of the combined
death/transplant outcome.
NSBB (propranolol, nadolol) were used in 87% of
patients included in the meta-analysis and the remaining
13% were on a therapy without an effect on portal
pressure (placebo or endoscopic therapy). A sensitivity
analysis that excluded the 4 studies with patients on
inactive therapy yielded the same results on outcomes
and death/transplant rates (data shown in
Supplementary Table 2).
Our meta-analysis is unique in that not only did we
explore outcomes other than variceal hemorrhage and
death, but we explored outcomes relevant to each prog-
nostic stage. In addition, because data were requested from
the original authors, we could ensure that duplicate pa-
tients were excluded and, therefore, unlike other meta-
analyses that extracted data from publications that had
duplicate patients, we report data on unique patients with
cirrhosis.FLA 5.6.0 DTD  YJCGH56552_proof Limitations of the study were those inherent to the
collection of retrospective selected data from prospective
studies. In addition, some important variables such as
comorbidities, hepatocellular carcinoma, Child–Pugh
score, and model for end-stage liver disease, were not
collected uniformly, therefore we were not able to
explore the impact of these predictive scores on out-
comes. Notably, although the second most common eti-
ology was viral, all studies were performed before the
advent of effective antiviral therapy and such therapy
therefore would not represent a confounder. A potential
confounder was the use (or not) of alcohol during the
study. Although alcohol was the etiology in fewer than
half of the patients (n ¼ 516), 9 of 15 studies reported on
alcohol abstinence during the follow-up evaluation. Of
these, 2 studies20,22 reported that all patients had been
abstinent during the study, 5 studies18,19,25,27,31 showed
no significant differences between alcohol abstinence/
nonabstinence and HVPG response/nonresponse, and
only 2 studies17,29 comprising only 110 patients found a
higher percentage of alcohol abstinence among HVPG
responders compared with nonresponders. Therefore, it
is unlikely that better outcomes in HVPG responders
observed in this meta-analysis could have been ascribed
to alcohol abstinence.
Reductions in HVPG all were described as threshold
reductions (responders vs nonresponders) in the studies
included in this meta-analysis. It may well be that anal-
ysis of absolute changes in mm Hg could provide more
granularity (as recently described36), but data on indi-
vidual data were not requested from the original authors
(only data on responders vs nonresponders), and
therefore such analysis could not be performed.
In summary, our results show that HVPG re-
sponders to NSBB-based pharmacologic therapy,
mainly defined as a reduction in HVPG to less than 12
mm Hg or a more than 20% reduction from baseline,
have a significantly lower risk of developing clinically
relevant outcomes in both patients with and without
ascites. In patients without ascites but with varices,
lowering portal pressure significantly reduces the risk
of any clinical decompensation (not only variceal
bleeding but also ascites and encephalopathy) and
improves survival. In patients with ascites (decom-
pensated) with or without variceal hemorrhage, a
reduction in portal pressure lowers the risk of further
decompensation (variceal hemorrhage, refractory as-
cites, spontaneous bacterial peritonitis, or encepha-
lopathy). Importantly, achieving an HVPG response
improves survival in patients with ascites and a pre-
vious episode of bleeding who are notoriously those
patients with the poorest survival rate. By showing
that reductions in portal pressure induced by NSBB-
based pharmacologic therapy improve outcomes and
decrease mortality, our study supports the use of
NSBB in all clinical settings (primary or secondary
prophylaxis) and in both patients with or without
ascites.26 June 2019  11:22 pm  ce DVC
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Supplementary Figure 1. Flowchart. AASLD, American Association for the Study of Liver Diseases; EASL, European Asso-
ciation for the Study of the Liver; HVPG, hepatic venous pressure gradient.
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Supplementary Figure 2. Patients included in studies of primary prophylaxis of variceal hemorrhage. Outcome: any clinical event Q26.
Supplementary Figure 3. Patients included in studies of primary prophylaxis of variceal hemorrhage. Outcome: death or
transplant.
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Supplementary Figure 4. Patients included in studies of secondary prophylaxis of variceal hemorrhage. Outcome: any clinical
event Q27.
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Supplementary Figure 5. Patients included in studies of primary prophylaxis of variceal hemorrhage. Outcome: death or
transplant.
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Supplementary Table 2.Outcomes of Patients on Active Pharmacologic Therapy
Benefit of responders vs nonresponders
Any clinical eventa Death/transplant
Overall effect P
Primary vs secondary





ascites (n ¼ 458)
OR, 0.35
(0.22–0.56)
<.0001 Primary (n ¼ 196)
OR, 0.28
(0.13–0.58)

















<.0001 Primary (n ¼ 120)
OR, 0.38
(0.16–0.89)













NOTE Q30. n ¼ 768. Numbers in parentheses represent 95% CI.
aIn patients without ascites: variceal bleeding (first in primary prophylaxis studies, recurrent in secondary prophylaxis studies), development of ascites or encephalopathy. In patients with ascites: development of variceal
bleeding (first in primary prophylaxis studies, recurrent in secondary prophylaxis studies) or refractory ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, or encephalopathy.
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